Adenine arabinoside in severe thrombocytopenia due to hemorrhagic varicella.
An 18-year-old man, admitted because of severe bleeding manifestations due to varicella thrombocytopenia was administered 800 mg/day adenine arabinoside (Ara-A) intravenously for 5 days. 2 days after the start of this treatment the bleeding phenomena became markedly reduced and a progressive increase in the platelet count was noted thereafter. Although a spontaneous improvement is known to occur in patients with varicella thrombocytopenia, the rapid clinical improvement after the Ara-A administration is suggestive for its beneficial effect in the presented patient.
D000293:Adolescent; D001853:Bone Marrow / Q000648:ultrastructure; D002644:Chickenpox / Q000150:complications*; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D008297:Male; D008533:Megakaryocytes / Q000648:ultrastructure; D008854:Microscopy, Electron; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014740:Vidarabine / Q000627:therapeutic use*
D014740:Vidarabine